Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021:181:115-132.
doi: 10.1007/978-3-030-78311-2_7.

Current Management and New Developments in the Treatment of Myelodysplastic Syndrome

Shukaib Arslan  1 , Samer Khaled  1 , Ryotaro Nakamura  2
Affiliations
Review

Current Management and New Developments in the Treatment of Myelodysplastic Syndrome

Shukaib Arslan et al. Cancer Treat Res. 2021.

Abstract

Myelodysplastic syndrome (MDS) is a heterogeneous hematological neoplasm with a wide range of clinical presentations from isolated anemia to pancytopenia and propensity to transform to acute myeloid leukemia. MDS is characterized by morphologic bone marrow dysplasia and ineffective hematopoiesis resulting from a range of cytogenetic abnormalities and somatic gene mutations. Disease management varies from observation alone for low-risk disease to hypomethylating agents and hematopoietic cell transplantation (HCT) for higher risk disease. In this chapter, we review the classification, risk stratification, and optimal management of patients with MDS.

Keywords: 2 (MDS-EB1; 5q- syndrome; Allogeneic hematopoietic cell transplant (alloHCT); EB2); Hypomethylating agents; Myelodysplastic syndrome (MDS); Myelodysplastic syndrome with excess blast 1.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Steensma DP (2018) Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J 8(5):47 - PubMed - PMC - DOI
    1. Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Sole F et al (2012) Revised international prognostic scoring system for myelodysplastic syndromes. Blood 120(12):2454–2465
    1. Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD et al (2017) Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med 376(6):536–547 - PubMed - PMC - DOI
    1. Saiki JH, McCredie KB, Vietti TJ, Hewlett JS, Morrison FS, Costanzi JJ et al (1978) 5-azacytidine in acute leukemia. Cancer 42(5):2111–2114 - PubMed - DOI - PMC
    1. Silverman LR, Demakos EP, Peterson BL, Kornblith AB, Holland JC, Odchimar-Reissig R et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol: Official J Am Soc Clin Oncol 20(10):2429–2440 - DOI

MeSH terms

LinkOut - more resources